Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28538236 | 0.85 | EPHX2 (0.34) | TP53PPARARAB9AMAPTEPHX2 | |
| SCHEMBL28202476 | 0.84 | TP53 (0.32) | TP53PPARARAB9AMAPTEPHX2 | |
| SCHEMBL28536124 | 0.77 | SMN1; SMN2 (0.36) | SMN1; SMN2RAB9AMAPTEPHX2NPC1 | |
| SCHEMBL9285410 | 0.73 | — | — | |
| SCHEMBL18255995 | 0.73 | HSP90AA1 (0.38) | TP53PPARASMN1; SMN2RAB9AEPHX2 | |
| SCHEMBL28538247 | 0.73 | EPHX2 (0.37) | PPARASMN1; SMN2RAB9AMAPTEPHX2 | |
| SCHEMBL14069081 | 0.73 | PPARA (0.33) | TP53PPARARAB9AEPHX2NPC1 | |
| SCHEMBL18256146 | 0.71 | PPARA (0.37) | TP53PPARARAB9AEPHX2ALDH1A1 | |
| SCHEMBL29241087 | 0.71 | NOTUM (0.40) | TP53SMN1; SMN2RAB9AMAPTEPHX2 | |
| SCHEMBL19987769 | 0.69 | ALDH1A1 (0.35) | TP53SMN1; SMN2RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | TP53 3985/4885PPARA 2378/4885SMN1; SMN2 1786/4885 |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | TP53 3985/4885PPARA 2378/4885SMN1; SMN2 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.